| Anthony Chukwunonso Okereke, PHARMD | |
|
35829 Cabrillo Drive, Fremont, CA 94536 | |
| (510) 757-4333 | |
| Not Available |
| Full Name | Anthony Chukwunonso Okereke |
|---|---|
| Gender | Male |
| Speciality | Pharmacist - Pharmacotherapy |
| Location | 35829 Cabrillo Drive, Fremont, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356735120 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1835P1200X | Pharmacist - Pharmacotherapy | RPH71343 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Anthony Chukwunonso Okereke, PHARMD 35829 Cabrillo Dr, Fremont, CA 94536-5407 Ph: (510) 754-3956 | Anthony Chukwunonso Okereke, PHARMD 35829 Cabrillo Drive, Fremont, CA 94536 Ph: (510) 757-4333 |
News Archive
CSL Behring announced today that the company has been granted Orphan Drug Designation by the United States Food and Drug Administration for its novel recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).
Getting children to eat their vegetables can seem like an insurmountable task, but nutrition researchers at The University of Texas at Austin have found one way: school gardens and lessons on using what's grown in them.
Researchers at National Jewish Health have discovered a signaling pathway that is crucial to the devastating effects of acute lung injury. The data, obtained from cells, animals and ALI patients, suggest several potential therapeutic targets. Experimental blockade of one of the targets significantly reduced flooding of the lungs that is the hallmark of ALI.
EntreMed, Inc. today announced that it completed a registered direct offering of 5,791,505 shares of its common stock, at a purchase price of $0.518 per share, to an existing accredited institutional investor. The sale resulted in gross proceeds to the Company of approximately $3 million. The terms of the purchase were set forth in a stock purchase agreement between the parties dated April 16, 2010. The per share purchase price reflects a 20% discount to the volume weighted average price on April 15, 2010.
Adding more good news to last week's announcement that Nexavar (sorafenib) may be the first effective treatment for advanced liver cancer, researchers at the Lombardi Comprehensive Cancer Center at Georgetown University have uncovered a new molecular mechanism that may 'spontaneously' cause liver cancer.
› Verified 3 days ago
Dr. Ranjit Singh Kali-rai, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 45372 Whitetail Ct, Fremont, CA 94539 Phone: 510-600-5125 | |
Heumin Li, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 39400 Paseo Padre Pkwy, Fremont, CA 94538 Phone: 510-248-7577 | |
Rahat Katyal, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 790 Saltillo Pl, Fremont, CA 94536 Phone: 510-796-0884 Fax: 510-562-5194 | |
Frances Tan, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 779 Emerson Ct, Fremont, CA 94539 Phone: 408-966-9696 | |
Priti Chatwani, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 41766 Covington Dr, Fremont, CA 94539 Phone: 510-754-6479 | |
Kandie Ann Rago, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4020 Fremont Hub, Fremont, CA 94538 Phone: 510-791-9108 | |
Sejal Parikh, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3860 Decoto Rd, Fremont, CA 94555 Phone: 510-793-9798 |